載入中
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
前收盤價
US$37.37
+US$0.30 · +0.81%
盤後
US$37.3127
−US$0.0573 · -0.15%
10月12日 下午7:36 ET
盤中時間採用ET。市場資料可能有所延遲。
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
日內區間
目前US$37.37
52週區間
目前US$37.37
盤中時間採用ET。市場資料可能有所延遲。
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
日內區間
目前US$37.37
52週區間
目前US$37.37
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 37.23億 USD | 215.26億 USD | 164.74億 USD | 145.05億 USD | 84.17億 USD |
| 銷貨成本 | 3.09億 USD | 9.85億 USD | 2.26億 USD | — | — |
| 毛利 | 34.14億 USD | 205.41億 USD | 162.48億 USD | 145.05億 USD | 84.17億 USD |
| 研究與開發 | 15.6億 USD | 97.48億 USD | 76.3億 USD | 55.62億 USD | 41.81億 USD |
| 銷售、一般及管理費用 | 6.02億 USD | 37.9億 USD | 32.97億 USD | 26.76億 USD | 12.83億 USD |
| 營業費用 | 21.63億 USD | 138.38億 USD | 109.27億 USD | 82.38億 USD | 54.64億 USD |
| 利息收入 | 1.38億 USD | 9.95億 USD | 9.39億 USD | 3.24億 USD | 1.97億 USD |
| 利息支出 | 6104.81萬 USD | 1.2億 USD | 2700萬 USD | 2100萬 USD | 1300萬 USD |
| 折舊和攤銷 | 7105.6萬 USD | 4.13億 USD | 2.94億 USD | 3.62億 USD | 2.49億 USD |
| 營業利益 | 12.51億 USD | 67.03億 USD | 53.21億 USD | 62.67億 USD | 29.53億 USD |
| 淨利 | 9.64億 USD | 78.44億 USD | 43.52億 USD | 54.52億 USD | 29.57億 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$44.75
上漲空間 19.75%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2018年5月1日 | 5:1 | — | — |
已生效 2018年5月1日
5:1
報告持有此股票曝險的交易所交易基金。
iShares Biotechnology ETFIBB1.59億1.47%108.2億 USD0.44%US$204.26-1.08%
First Trust NYSE Arca Biotechnology Index FundFBT1.16億4.00%28.91億 USD0.55%US$263.9-0.57%
Avantis International Equity ETFAVDE1872.77萬0.10%192.24億 USD0.23%US$89.58-0.24%
Tema Oncology ETFCANC755.28萬3.68%2.05億 USD0.99%US$40.5781-0.50%
First Trust Nasdaq BuyWrite Income ETFFTQI256.42萬0.25%10.15億 USD0.75%US$22.39-0.22%
Harding Loevner International Developed Markets Select Equity ETFLOEV221.05萬2.45%8946.69萬 USD0.70%US$15.98-0.06%
John Hancock Investments - Multifactor Developed International ETFJHMD194.69萬0.20%9.83億 USD0.39%US$43.96-0.29%
ActivePassive International Equity ETFAPIE100.43萬0.09%11.41億 USD0.45%US$38.40-0.41%iShares Biotechnology ETFIBBFirst Trust NYSE Arca Biotechnology Index FundFBTAvantis International Equity ETFAVDETema Oncology ETFCANCFirst Trust Nasdaq BuyWrite Income ETFFTQIHarding Loevner International Developed Markets Select Equity ETFLOEVJohn Hancock Investments - Multifactor Developed International ETFJHMDActivePassive International Equity ETFAPIEAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
